Management of CKD Stage G3a (eGFR 45‑59 mL/min/1.73 m²)
1. Diagnostic Work‑up
- Measure urine albumin‑to‑creatinine ratio (ACR) immediately – the single most critical test to guide staging and treatment decisions in CKD G3a. [KDIGO 2024] 1
- Confirm chronicity by verifying that reduced kidney function has persisted ≥ 3 months (review prior creatinine values or repeat testing). [KDIGO 2014] 4
- Screen for systemic contributors (diabetes, dyslipidaemia, hypertension) with HbA1c, fasting glucose, lipid panel and blood pressure measurement. [KDIGO 2024; American Diabetes Association 2022] [2][5]
- Investigate unexplained elevated hematocrit in CKD with a complete blood count with differential, erythropoietin level, and renal ultrasound to rule‑out secondary polycythemia, renal neoplasms, or cystic disease. [KDIGO 2024; KDIGO 2014] [2][4]
2. Risk Stratification (KDIGO Criteria)
| ACR (mg/g) | Risk Category (for eGFR 45‑59) | Guideline |
|---|---|---|
| < 30 | Moderate risk | [KDIGO 2024] [1] |
| 30‑300 | High risk | [KDIGO 2024] [1] |
| > 300 | Very high risk | [KDIGO 2024] [1] |
3. Blood‑Pressure & Cardiovascular Risk Management
- Target blood pressure < 120/80 mmHg if tolerated without symptomatic hypotension, to slow CKD progression. [KDIGO 2024; KDIGO 2024] [2][3]
- Optimize glycaemic control (HbA1c < 7 % for most patients with diabetes). [American Diabetes Association 2022] 5
- Initiate statin therapy for lipid management in all CKD patients at increased cardiovascular risk. [American Diabetes Association 2022] 5
- Promote smoking cessation when applicable. [American Diabetes Association 2014] 6
4. Pharmacologic Therapy
4.1 Renin‑Angiotensin System (RAS) Inhibitors
- Start an ACE‑inhibitor or ARB at the highest tolerated dose for any patient with ACR ≥ 30 mg/g.
- Diabetic patients: Strong recommendation (Grade 1B). [2][3]
- Non‑diabetic patients:
- ACR > 300 mg/g – Strong recommendation (Grade 1B). [2][3]
- ACR 30‑300 mg/g – Conditional recommendation (Grade 2C). [2][3]
- Monitoring: Check serum creatinine and potassium 2‑4 weeks after initiation; discontinue only if creatinine rises > 30 % within 4 weeks or uncontrolled hyperkalaemia occurs. [2][3]7
- Do not stop the RAS inhibitor for creatinine increases ≤ 30 % in the absence of volume depletion. 5
4.2 Sodium‑Glucose Co‑Transporter‑2 (SGLT2) Inhibitors
| Patient group | Indication | Recommendation strength |
|---|---|---|
| Type 2 diabetes + CKD (eGFR ≥ 20) | Initiate SGLT2i | Strong (Grade 1A) |
| Non‑diabetic CKD with ACR ≥ 200 mg/g (eGFR ≥ 20) | Initiate SGLT2i | Strong (Grade 1A) |
| Non‑diabetic CKD with ACR < 200 mg/g (eGFR 20‑45) | Consider SGLT2i | Conditional (Grade 2B) |
- Continue SGLT2i even if eGFR falls below 20 mL/min/1.73 m² unless intolerable or patient starts dialysis. [2][3]7
- Withhold during prolonged fasting, surgery, or critical illness. [2][3]
4.3 Non‑steroidal Mineralocorticoid Receptor Antagonist (Finerenone)
- Consider finerenone for patients with type 2 diabetes, persistent albuminuria (> 30 mg/g) despite maximally tolerated RAS inhibitor and SGLT2i, provided eGFR > 25 mL/min/1.73 m² and normal serum potassium. Strong recommendation. [2][3]5
5. Monitoring Strategy
- Repeat ACR and eGFR annually if stable; every 3‑6 months when albuminuria ≥ 30 mg/g or eGFR is declining. 5
- Aim for ≥ 30 % reduction in albuminuria (when baseline ≥ 300 mg/g) to decelerate CKD progression. 5
- Surveillance for CKD complications (anemia, bone‑mineral disorder, metabolic acidosis) should be performed routinely. 4
6. Common Pitfalls & Safety Alerts
- Do not discontinue RAS inhibitors for creatinine rises < 30 % – such changes are expected and beneficial. [2][3]7
- Initial eGFR dip with SGLT2 inhibitors is reversible and not an indication to stop therapy. [2][3]
- Avoid triple blockade (ACE‑inhibitor + ARB + direct renin inhibitor) because it increases harm without added benefit. [2][3]
All facts are derived from guideline societies (KDIGO, American Diabetes Association) and include the strength of evidence where specified.